A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease

Back to table of contents Previous article Next article No AccessA double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's diseasePublished Online:1 Apr 2006https://doi.org/10.1176/ajp.150.2.321AboutSectionsView articleAbstractPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail View articleAbstractThe potential efficacy of oral l-deprenyl (5 mg b.i.d.) added to the regimen of 10 patients with Alzheimer's disease receiving either tacrine or physostigmine was assessed in a double-blind, placebo- controlled, 4-week, two-period crossover pilot study. l-Deprenyl was associated with significant improvement in scores on the cognitive subscale of the Alzheimer's Disease Assessment Scale, suggesting possible additive effects of l-deprenyl to the effects of cholinesterase inhibitors. Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Purchase Save for later Item saved, go to cart PPV Articles - American Journal of Psychiatry $35.00 Add to cart PPV Articles - American Journal of Psychiatry Checkout Please login/register if you wish to pair your device and check access availability. Not a subscriber? Subscribe Now / Learn More PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development. Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.). FiguresReferencesCited byDetailsCited bySite-activated multi target iron chelators with acetylcholinesterase (AChE) and monoamine oxidase (MAO) inhibitory activities for Alzheimer’s disease therapy21 February 2022 | Journal of Neural Transmission, Vol. 129, No. 5-6From Anti-Parkinson’s Drug Rasagiline to Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimer’s Disease5 November 2022From Anti-Parkinson’s Drug Rasagiline to Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimer’s Disease27 February 2020ChemMedChem, Vol. 11, No. 11Molecular Medicine Reports, Vol. 9, No. 5Site-Activated Chelators Targeting Acetylcholinesterase and Monoamine Oxidase for Alzheimer’s Therapy19 May 2010 | ACS Chemical Biology, Vol. 5, No. 6Discovery of a Novel Class of Potent Coumarin Monoamine Oxidase B Inhibitors: Development and Biopharmacological Profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2 H -chromen-2-one Methanesulfonate (NW-1772) as a Highly Potent, Selective, Reversible, and Orally Active Monoamine Oxidase B Inhibitor7 October 2009 | Journal of Medicinal Chemistry, Vol. 52, No. 21The American Journal of Geriatric Psychiatry, Vol. 17, No. 9Multi-target-Directed Ligands To Combat Neurodegenerative Diseases9 January 2008 | Journal of Medicinal Chemistry, Vol. 51, No. 3Treating Alzheimer's disease: Do clinical trial methods produce unnecessary practitioner dilemmas?4 September 2016 | American Journal of Alzheimer's Disease & Other Dementiasr, Vol. 21, No. 2European Journal of Pharmacology, Vol. 518, No. 2-3Journal of Pharmacology and Experimental Therapeutics, Vol. 309, No. 3Expert Review of Neurotherapeutics, Vol. 4, No. 5Cochrane Database of Systematic ReviewsTreatment of Alzheimer's Disease (With or Without Cerebrovascular Disease)14 January 2008Classes of Psychotropicsa Overview of Evidence from Clinical Trials14 January 2008International Journal of Geriatric Psychiatry, Vol. 17, No. 2Physostigmine for dementia due to Alzheimer's disease23 April 2001 | Cochrane Database of Systematic Reviews, Vol. 58Behavioural Brain Research, Vol. 115, No. 2Application of the Changing Therapies for Alzheimer's Disease in Clinical PracticePerspectives on Gerontology, Vol. 3, No. 1, Vol. 54Neuropraxis, Vol. 2, No. 4Short-Term Administration of Selegiline for Mild-to-Moderate Dementia of the Alzheimer's TypeThe American Journal of Geriatric Psychiatry, Vol. 6, No. 2, Vol. 34Rational pharmacotherapy for Alzheimer's diseaseMedical Update for Psychiatrists, Vol. 2, No. 1CNS Spectrums, Vol. 2, No. 4Selegiline in Treatment of Behavioral and Cognitive Symptoms of Alzheimer Disease28 June 2016 | Annals of Pharmacotherapy, Vol. 30, No. 10Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 6Psychiatry Research, Vol. 58, No. 3Reviews in Clinical Gerontology, Vol. 5, No. 2The treatment of Alzheimer's disease2 July 2016 | Journal of Psychopharmacology, Vol. 9, No. 1International Review of Psychiatry, Vol. 5, No. 4 Volume 150Issue 2 February 1993Pages 321-323 Metrics PDF download History Published online 1 April 2006 Published in print 1 February 1993